China overtook Japan as the world’s second-biggest healthcare market in 2013, and with its annual healthcare spending forecast to reach nearly US$900bn by 2018, it will rapidly close the gap on the US, reports the Economist Intelligence Unit (EIU).
China overtook Japan as the world’s second-biggest healthcare market in 2013, and with its annual healthcare spending forecast to reach nearly US$900bn by 2018, it will rapidly close the gap on the US, reports the Economist Intelligence Unit (EIU).
EIU’s China Healthy Province Index (CHPI) provides a detailed healthcare profile of each of China’s 31 provinces,ranking provinces according to which are best placed in terms of resources and financing to meet current and anticipated healthcare demand. Beijing tops the CHPI, but one of the surprising outcomes was the strong performance of poorer provinces such as Qinghai and Gansu. Sparse populations in such regions ease pressure on local healthcare systems. Those that bottomed out include the rapidly developing central provinces of Henan and Anhui, densely populated regions where access to healthcare and funding is low despite booming local demand.
The EIU also reports how the Chinese government has been opening up the healthcare system to private sector investment, but warns that stresses in the system our mounting, as popular frustration over costs and access begins to “boil over”.
More information: http://www.eiu.com/chpi2014
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.